cilostazol has been researched along with 15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukuda, Y; Fukuta, Y; Higashino, R; Ito, S; Kurimoto, T; Nomura, Y; Sato, R; Takei, M; Tamaki, H; Tanaka, T | 1 |
1 other study(ies) available for cilostazol and 15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid
| Article | Year |
|---|---|
Antiplatelet effect of Z-335, a new orally active and long-lasting thromboxane receptor antagonist.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Biphenyl Compounds; Cilostazol; Drug Interactions; Fibrinolytic Agents; Guinea Pigs; Heptanoic Acids; Humans; Indans; Male; Mice; Mice, Inbred ICR; Phenylacetates; Platelet Aggregation; Platelet Aggregation Inhibitors; Pulmonary Embolism; Receptors, Thromboxane; Sulfonamides; Tetrazoles; Vasoconstrictor Agents | 1998 |